Epistaxis During Antiplatelet and Anticoagulant Therapy in Patients with Cardiovascular Disease: Clinical Dilemmas, Guideline Comparison, and a Personalized Management Algorithm
Diseases · 12.11.2026 · 14 (11) · 414
DOI: 10.3390/diseases14110414 ↗Kurz gefasst
Leitlinie in der Zeitschrift Diseases, online erschienen am 12.11.2026. Verfasst von Zhanetta Mukanova und 16 weiteren Autor:innen. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objective. Epistaxis is a frequent bleeding manifestation in patients receiving antithrombotic therapy, and its management falls between otolaryngology and cardiology guidance. We aimed to translate the evidence into an operational framework for joint decisions.
Methods
PubMed/MEDLINE, Scopus, Embase, and the Cochrane Library were searched (January 2015 through August 2026), current ESC, ACC/AHA, EHRA, AAO-HNS, and SFORL guidance were analyzed, and national clinical protocols of different countries were screened; 67 sources were included.
Results
Direct oral anticoagulants were consistently associated with fewer clinically relevant epistaxis events than warfarin, and minor epistaxis led to permanent anticoagulant discontinuation more often than minor bleeding at other sites. No guideline defines epistaxis severity, and guidance diverges on protected dual antiplatelet therapy, bleeding-risk assessment, and the sequence of local hemostasis and drug interruption. We propose a three-tier severity classification (minor, clinically relevant non-major, major) informed by ISTH and BARC definitions, a pragmatic thrombotic risk stratification, and an algorithm with agent-specific decisions.
Conclusions
In minor and most clinically relevant non-major episodes, antithrombotic therapy can usually be continued while local hemostasis is achieved; interruption, de-escalation, or reversal should be individualized and reserved for uncontrolled or major bleeding. Effective local hemostasis can help avoid unnecessary interruption of antithrombotic therapy, and otolaryngologists should be part of multidisciplinary teams managing such bleeding.
Zitieren
APA
Mukanova, Z., Zhangelova, S., Kapsultanova, D., Mukanov, K., Nurbay, Z., Nurgaliyeva, G., Izhanova, A., Almukhanova, A., Zhansarina, G., Tokbulatova, M., Issabekova, A., Toktarova, Z., Sugraliyev, A., Rustamova, F., Suatbayeva, R., Imangaliyeva, A., & Nurmukhammad, F. (2026). Epistaxis During Antiplatelet and Anticoagulant Therapy in Patients with Cardiovascular Disease: Clinical Dilemmas, Guideline Comparison, and a Personalized Management Algorithm. Diseases, 14(11), 414. https://doi.org/10.3390/diseases14110414
Vancouver
Mukanova Z, Zhangelova S, Kapsultanova D, Mukanov K, Nurbay Z, Nurgaliyeva G, et al. Epistaxis During Antiplatelet and Anticoagulant Therapy in Patients with Cardiovascular Disease: Clinical Dilemmas, Guideline Comparison, and a Personalized Management Algorithm. Diseases. 2026;14(11):414. doi:10.3390/diseases14110414
BibTeX
@article{Mukanova2026,
author = {Mukanova, Zhanetta and Zhangelova, Sholpan and Kapsultanova, Dina and Mukanov, Kanatbek and Nurbay, Zhanar and Nurgaliyeva, Gulzada and Izhanova, Aigyul and Almukhanova, Aizhan and Zhansarina, Galiya and Tokbulatova, Meiramgul and Issabekova, Assel and Toktarova, Zhanar and Sugraliyev, Akhmetzhan and Rustamova, Farida and Suatbayeva, Rimma and Imangaliyeva, Assel and Nurmukhammad, Friba},
title = {Epistaxis During Antiplatelet and Anticoagulant Therapy in Patients with Cardiovascular Disease: Clinical Dilemmas, Guideline Comparison, and a Personalized Management Algorithm},
journal = {Diseases},
year = {2026},
volume = {14},
number = {11},
pages = {414},
doi = {10.3390/diseases14110414}
}
EUVIMED